Half-life of single-chain urokinase-type plasminogen activator (scu-PA) and two-chain urokinase-type plasminogen activator (tcu-PA) in patients with acute myocardial …
M Köhler, S Sen, C Miyashita, R Hermes, G Pindur… - Thrombosis research, 1991 - Elsevier
The pharmacokinetics of urokinase (two-chain urokinase-type plasminogen activator, tcu-
PA) and single-chain urokinase-type plasminogen activator (scu-PA) were studied in 20
patients with acute myocardial infarction (AMI). Ten consecutive patients received 2.5 million
units tcu-PA by bolus injection within 5 min during the first 6 h after AMI (group I). Ten further
consecutive patients received 250,000 U tcu-PA within 5 min, followed by 4.5 million U scu-
PA by intravenous infusion over 40 min (group II). An enzyme immunoassay was developed …
PA) and single-chain urokinase-type plasminogen activator (scu-PA) were studied in 20
patients with acute myocardial infarction (AMI). Ten consecutive patients received 2.5 million
units tcu-PA by bolus injection within 5 min during the first 6 h after AMI (group I). Ten further
consecutive patients received 250,000 U tcu-PA within 5 min, followed by 4.5 million U scu-
PA by intravenous infusion over 40 min (group II). An enzyme immunoassay was developed …